US giant LabCorp signs up for GTG license
09 February, 2004 by Melissa TrudingerMelbourne company Genetic Technologies (ASX:GTG) has added another large US company to its tally, with Laboratory Corporation of America Holdings -- otherwise known as LabCorp -- becoming the latest to license the company's non-coding DNA mapping and analysis patents.
Vaccine firm names new CEO
06 February, 2004 by Graeme O'NeillCanberra vaccine developer Vaxine has appointed Ted Stapinski, a 20-year veteran of Australia's space industry, as its new CEO.
AusBiotech to strengthen NZ ties
05 February, 2004 by Melissa TrudingerIndustry body AusBiotech and its New Zealand counterpart, NZBio, are planning to work together on a number of projects this year to strengthen ties between the two countries and promote the capabilities of the region.
HECS fee cut no windfall for science, says expert
22 January, 2004 by Graeme O'NeillMacquarie University's decision to waive or reduce Higher Education Contribution Scheme (HECS) fees for some science and technology subjects is likely to have little impact on students' choices about where and what they study, according to a Melbourne expert on education policy.
BresaGen goes into voluntary administration
20 January, 2004 by Melissa TrudingerAustralian biotechnology veteran BresaGen (ASX:BGN) has gone into voluntary administration.
Bionomics reports healthy bank balance
20 January, 2004 by Graeme O'NeillAdelaide biotech Bionomics (ASX:BNO) has reported that it had nearly AUD$5 million in the bank at the end of the December 2003 quarter, giving it enough cash for at least two years at its current burn rate.
FEATURE: Why biotech recruiters are confident in '04
08 January, 2004 by Melissa TrudingerThe slump in the Australian biotechnology industry in the first half of 2003 was reflected in the recruitment market, according to leading recruitment consultants.
AusBiotech hails 'exceptional' talent in new board line-up
16 December, 2003 by Melissa TrudingerAusBiotech members have elected Johnson & Johnson Research managing director Susan Pond, venture capitalist Leigh Farrell and former Amrad managing director Sandra Webb as corporate directors to its board, after a tight race between nine candidates. Western Australian Biomedical Research Institute director Simon Carroll was also re-elected as an institutional director.
Critical mass key to investor support: Vernalis CEO
09 December, 2003 by Melissa TrudingerSmall biotech companies face investor resistance to mergers and acquisitions, a leading British biotech CEO told attendees at a briefing in Melbourne on Tuesday.
Did BIF offer bang for its buck?
08 December, 2003 by Michael VitaleThe fifth round of Biotechnology Innovation Fund (BIF) grants, announced late last month by Federal Industry Minister Ian Macfarlane, is the final funding round for the $40 million program. Over its lifetime, the BIF scheme has supported 164 projects in 153 companies, ranging from tiny start-ups to listed giants such as Orica.
Peter Mac spin-off nets European funding
27 November, 2003 by Melissa TrudingerThe Peter MacCallum Cancer Centre has spun out its cellular therapies services into a small company called Cell Therapies, in order to make the most of its TGA-licensed Centre for Blood Cell Therapies.
British Columbia's Discovery Parks a good model for Australia
20 November, 2003 by Melissa TrudingerThe developer of British Columbia's Discovery Parks -- technology parks based on four campuses around the Canadian province -- believes the Discovery Park model would be advantageous to the development of Australian innovation and technology.
Strategic alliances between Victoria and China flagged
20 November, 2003 by Melissa TrudingerVictoria has signed a Memorandum of Understanding with Chinese sister state Jiangsu Province calling for strategic biotechnology alliances and joint ventures.
Academics should not fear industry involvement, says Canadian prof
20 November, 2003 by Melissa TrudingerAcademic researchers need a bit of encouragement to take the plunge into biotechnology, according to visiting University of British Columbia professor and biotechnology company founder Bob Hancock.
Dendritic Nanotechnologies granted self-assembly patents, gets funding boost
19 November, 2003 by Graeme O'NeillLeading US nanotechnology innovator Dendritic Nanotechnologies (DNT) continues to shine for its associate and 49.9 per cent owner Melbourne drug-developer Starpharma (ASX: SPL), after being granted a US patent on a new self-assembly technique for its giant, branched molecules, called dendrimers.
